BridgeMD
Compares treatment options for Metastatic Pancreatic Ductal Adenocarcinoma
Official title A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov ID: NCT07490301
What this study is testing
What is Telisotuzumab adizutecan?
Telisotuzumab adizutecan is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for metastatic pancreatic ductal adenocarcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have unresectable, metastatic histologically- or cytologically-confirmed adenocarcinoma of the pancreas
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Must consent to provide archived or recently obtained tumor tissue during Screening
- Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You likely can't join if
- Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or metastatic setting
- Prior c-MET targeting therapy
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis...
- Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.
The study team makes the final eligibility decision.
Where it's taking place
- Zion, Illinois, United States
- Grand Rapids, Michigan, United States
- Tyler, Texas, United States
- Fairfax, Virginia, United States
- North Tamworth, New South Wales, Australia
- Randwick, New South Wales, Australia
- Clayton, Victoria, Australia
- Murdoch, Western Australia, Australia
- Ramat Gan, Tel Aviv, Israel
- Tel Aviv, Tel Aviv, Israel
- Haifa, Israel
- Jerusalem, Israel
- Pisa, Italy
- Koto-ku, Tokyo, Japan
- Seoul, Seoul Teugbyeolsi, South Korea
- Kaohsiung City, Taiwan
- Taichung, Taiwan
- Taipei, Taiwan
- Oxford, Oxfordshire, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Zion, Illinois, United States; Grand Rapids, Michigan, United States; Tyler, Texas, United States; Fairfax, Virginia, United States; North Tamworth, New South Wales, Australia; Randwick, New South Wales, Australia and 13 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.